... of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing ...
... needs of 16,300 employees and contractors at Genentech Inc., Pierce took a chance and decided ... Genentech own the technology. Instead, Pierce decided to rent these indispensable products from Google Inc ...
... AP) -- Genentech Inc. on Monday touted its culture of innovative research and offered detailed long-term sales ...
WASHINGTON, April 9 (UPI) -- The U.S. Food and Drug Administration says Genentech Inc. is withdrawing the psoriasis drug Raptiva and it will no longer be available in the United States.
... abnormality, are associated with either overexpression or perpetual activation of the protein FGFR3. A team of researchers, at Genentech Inc., South San Francisco, has now ...
... . The gold standard of treatment is ranibizumab (Lucentis, Genentech Inc.), which was FDA approved for AMD in 2006. Bevacizumab (Avastin, Genentech Inc.) was FDA approved for colo-rectal cancer in 2004, and has since ...
... not halt IgE production and patients need to be treated repeatedly. But now, a team of researchers, at Genentech Inc., South San Francisco, has developed ...
... genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche ... with high confidence. This depth of sequencing enabled the Genentech researchers to identify a large number of somatic ...
... Institute (NCI) under a Cooperative Research and Development Agreement Letter of Intent between NCI and Genentech, Inc. St. Jude is home to the nation ...
... (NIAID), part of the National Institutes of Health, and the Juvenile Diabetes Research Foundation International. Genentech Inc., of South San Francisco, Calif ...
... of treatment for wet AMD is ranibizumab (Lucentis, Genentech Inc.), which was FDA approved as an eye injection in 2006. Bevacizumab (Avastin, Genentech Inc.) was FDA approved for the treatment of colorectal cancer in 2004 ...
... disease are among the risk factors for RVO. Winifred Werther, Ph.D., then of Genentech Inc., South San Francisco, Calif., now of Vertex Pharmaceuticals, Cambridge, Mass., and colleagues ...
... , Ph.D., chairman and former CEO of Genentech Inc., will receive the Fifth Annual American Association for Cancer Research Margaret Foti Award ...
... , with the use of a protein network map established by researchers at Genentech Inc., Stanford University and the University of California ... authors were Peter Jackson and Liyun Sang at Genentech and Jeremy Reiter at UCSF. Other collaborators included ...
... to establish its efficacy in treating some types of leukaemia and lymphoma. Navitoclax is being jointly developed by Abbott and Genentech, Inc. Dr Visvader said combined treatment ...
